🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 14 of 116

  1. METHOTREXATE, IFOSFAMIDE, VINCRISTINE, CYCLOPHOSPHAMIDE, RITUXIMAB, ETOPOSIDE, CYTARABINE, PREDNISOLONE, DOXORUBICIN

    Wuhan Createrna Science and Technology Co., Ltd

    Burkitt lymphoma

    phase 3 small molecule active

    1 trial

  2. METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. METOCLOPRAMIDE , -, SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion, OCTREOTIDE

    Novartis Pharmaceuticals

    Gastroenteropancreatic neuroendocrine tumor (GEP-NET)

    phase 3 small molecule active

    1 trial

  4. MIDOSTAURIN, ARACYTIN 500 mg/10 ml Polvere e Solvente per Soluzione Iniettabile, DAUNORUBICIN HYDROCHLORIDE

    Fondazione Telethon ETS

    Acute Myeloid Leukemia (LMA) with FLT3 mutation

    phase 3 small molecule active

    1 trial

  5. MIE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Carcinoma

    phase 3 other active

    1 trial

  6. MITOMYCIN , JNJ-42756493, GEMCITABINE

    Janssen-Cilag International N.V.

    High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations

    phase 3 small molecule active

    1 trial

  7. MK-1022, CAPECITABINE , PACLITAXEL , TRASTUZUMAB DERUXTECAN , PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  8. MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  9. MK-2870, GEMCITABINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , -, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 small molecule active

    1 trial

  10. MK-2870, PACLITAXEL ALBUMIN-BOUND, -, PACLITAXEL , -, -, DOXORUBICIN , PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  11. MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

  12. MK-3543, MK-3543, MK-3543, MK-3543

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

  13. MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB

    Merck Sharp and Dohme

    Colorectal Cancer

    phase 3 small molecule active

    1 trial

  14. MRI

    United Therapeutics Europe Ltd

    Prostate Neoplasm

    phase 3 other completed

    1 trial

  15. MRTX1719, CARBOPLATIN, CISPLATIN, PEMETREXED, MRTX1719 Matching Placebo, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, PACLITAXEL

    Bristol-Myers Squibb Australia Pty Ltd

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  16. MTX

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gestational Trophoblastic Tumor

    phase 3 small molecule active

    1 trial

  17. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  18. MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  19. MabThera 500 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Glofitamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed or refractory diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  20. MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion., GEMCITABINE , OXALIPLATIN

    Hoffmann-La Roche

    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  21. Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study

    The George Institute

    Maintenance treatment in metastatic non-squamous lung cancer

    phase 3 other active

    1 trial

  22. Medpulser Electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head Neck Cancer

    phase 3 other terminated

    1 trial

  23. Megestrol（Yining）

    The First People's Hospital of Lianyungang

    Stage III Esophageal Squamous Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  24. Methylthioninium

    Shandong Suncadia Medicine Co.,

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  25. MiLES

    Turn Therapeutics

    Cancer

    phase 3 other active

    1 trial

  26. Micofenolato de mofetil Generis 250 mg Cápsulas, Inflectra 100 mg powder for concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Oxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie

    AstraZeneca AB

    Advanced Biliary Tract Cancers

    phase 3 small molecule active

    1 trial

  27. Mirvetuximab Soravtansine

    AbbVie

    Epithelial Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  28. Mirvetuximab soravtansine plus Bevacizumab

    AbbVie

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  29. Mitoxantrone Hydrochloride Liposome

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  30. Monalizumab, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, CETUXIMAB

    AstraZeneca AB

    Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

    phase 3 small molecule active

    1 trial

  31. Motesanib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  32. Mycofit, 250 mg, kapsułki twarde, volrustomig, Saline, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Locally advanced cervical cancer

    phase 3 small molecule active

    1 trial

  33. Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  34. Myocet

    Teva Pharma GmbH

    Early Primary Breast Cancer

    phase 3 small molecule completed

    1 trial

  35. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  36. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  37. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  38. NIS793

    Novartis Pharmaceuticals

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule completed

    1 trial

  39. NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL

    Amgen

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  40. NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  41. NKTR-102

    Nektar Therapeutics UK Limited

    Locally Recurrent Breast Cancer

    phase 3 small molecule completed

    1 trial

  42. NKTR-214

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab completed

    1 trial

  43. NKTR-214

    Bristol-Myers Squibb

    Melanoma

    phase 3 mab completed

    1 trial

  44. NKTR-255 at 1.5 µg/kg

    Nektar Therapeutics UK Limited

    Non-Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  45. NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg

    Ningbo Cancer Hospital

    Localised Very High-Risk Cancer of the Prostate

    phase 3 small molecule active

    1 trial

  46. NX-5948

    Nurix Therapeutics

    B-cell Lymphoma

    phase 3 small molecule active

    2 trials

  47. Nab-paclitaxel 80 mg/m^2

    CORCEPT THERAPEUTICS INC

    Ovarian Neoplasm

    phase 3 small molecule active

    1 trial

  48. Nadroparin, long term

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.